US2022080047A1PendingUtilityA1

Topical use of levofloxacin for reducing lung inflammation

70
Assignee: HORIZON ORPHAN LLCPriority: Oct 7, 2008Filed: Apr 26, 2021Published: Mar 17, 2022
Est. expiryOct 7, 2028(~2.2 yrs left)· nominal 20-yr term from priority
A61K 47/02A61K 45/06A61K 31/5383A61K 31/538A61K 31/7036A61P 11/06A61P 43/00A61P 31/04A61P 19/04A61P 7/02A61P 29/00A61P 11/08A61K 31/536C07D 498/14A61K 33/06A61P 11/00A61P 35/00Y02A50/30
70
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to methods and compositions for the treatment of pulmonary inflammation. In particular, methods and compositions using aerosol levofloxacin or ofloxacin to reduce pulmonary inflammation are provided.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for treating an acute or chronic inflammation of at least a portion of a respiratory tract in a subject in need thereof, the method comprising administering to the subject an aerosol of a solution comprising from about 90 mg/ml to about 110 mg/ml of levofloxacin and from about 190 mM to about 210 mM of a magnesium cation, a calcium cation, a zinc cation, a copper cation, an aluminum cation, or an iron cation; to treat the inflammation. 
     
     
         2 . The method of  claim 1 , wherein the solution comprises about 100 mg/ml of levofloxacin and about 200 mM of the magnesium cation. 
     
     
         3 . The method of  claim 2 , wherein the magnesium cation is in the form of magnesium chloride. 
     
     
         4 . The method of  claim 1 , wherein the solution has a pH from about 5 to about 8 and an osmolality from about 300 mOsmol/kg to about 500 mOsmol/kg. 
     
     
         5 . The method of  claim 1 , wherein the aerosol has a mass median aerodynamic diameter from about 2 microns to about 5 microns with a geometric standard deviation less than or equal to 2.5 microns 
     
     
         6 . A method for treating a pulmonary inflammation in a subject in need thereof, the method comprising administering to the subject an aerosol of a solution comprising from about 90 mg/ml to about 110 mg/ml of levofloxacin and from about 190 mM to about 210 mM of a magnesium cation, a calcium cation, a zinc cation, a copper cation, an aluminum cation, or an iron cation; to treat the pulmonary inflammation. 
     
     
         7 . The method of  claim 6 , wherein the pulmonary inflammation is an acute or chronic inflammation of a lung. 
     
     
         8 . The method of  claim 6 , wherein the pulmonary inflammation is an acute or chronic inflammation of an upper airway, 
     
     
         9 . The method of  claim 6 , wherein the solution comprises about 100 mg/ml of levofloxacin and about 200 mM of the magnesium cation. 
     
     
         10 . The method of  claim 9 , wherein the magnesium cation is in the form of magnesium chloride. 
     
     
         11 . The method of  claim 6 , wherein the solution has a pH from about 5 to about 8 and an osmolality from about 300 mOsmol/kg to about 500 mOsmol/kg. 
     
     
         12 . A method for treating a pulmonary inflammation in a subject in need thereof, the method comprising administering to the subject a solution comprising from about 90 mg/ml to about 110 mg/ml of levofloxacin and from about 190 mM to about 210 mM of a magnesium cation, a calcium cation, a zinc cation, a copper cation, an aluminum cation, or an iron cation; to treat the pulmonary inflammation; wherein the subject does not have a pulmonary bacterial infection. 
     
     
         13 . The method of  claim 12 , wherein the solution comprises about 100 mg/ml of levofloxacin and about 200 mM of the magnesium cation. 
     
     
         14 . The method of  claim 13 , wherein the magnesium cation is in the form of magnesium chloride. 
     
     
         15 . The method of  claim 12 , wherein the solution has a pH from about 5 to about 8 and an osmolality from about 300 mOsmol/kg to about 500 mOsmol/kg.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.